Game-changing Peter Mac research destroys cancer-causing RNA
Posted: 4 July 2024 Peter Mac researchers have taken the first step towards designing rapid personalised cancer treatments by ‘cutting out’ disease-causing RNA. The findings, published in Nature Structural & Molecular Biology Journal, demonstrate how an innovative technology called…
Completion of Recruitment of First 26 Patients in Phase 2A ACCENT Trial
Posted: 4 July 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that it has now recruited 26 patients in the Phase 2a stage of its clinical trial investigating narmafotinib in the treatment…
Are your environmental marketing claims compliant? – Legal Update
Posted: 4 July 2024 Businesses are increasingly making environmental sustainability claims when marketing their goods, services or investment products. Consumers are ever more conscious of environmental issues and are seeking to reduce the negative impact on the environment…
TGA targets businesses for unlawful advertising of prescription-only drugs
Posted: 4 July 2024 Companies involved in the supply of therapeutic goods in Australia must ensure that their advertising complies with the requirements of the Therapeutic Goods Act 1989 (Cth), the Therapeutic Goods Advertising Code (Advertising Code) and the Australian Consumer Law. The…
CSIRO partners to strengthen regional health
Posted: 2 July 2024 Australia’s national science agency, CSIRO, will partner with governments across the Pacific and Southeast Asia to help them better prepare for, and respond to, disease outbreaks. Emerging and endemic infectious diseases in humans and…
Medicines Development for Global Health receives $16M grant to progress two important global health medicines: moxidectin and dovramilast
Posted: 2 July 2024 Medicines Development for Global Health (MDGH) announces that it has received a AU$16M (~US$10.7M) grant from the Australian Government to advance the development and delivery of moxidectin for scabies and lymphatic filariasis and dovramilast…
Making More Life-Saving Medical Products Market Ready
Posted: 2 July 2024 The Allan Labor Government is supporting medical technology startups and scaleups to get their life-saving products into hospitals sooner – with new grants making it easier and more accessible for startups to enter the…
GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer
Posted: 27 June 2024 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has released its novel Comprehensive Risk Assessment…
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer
Posted: 27 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces topline results from the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial…
INOVIQ isolates brain-derived exosomes in Alzheimer’s
Posted: 27 June 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that its NEURO-NET™ technology can isolate brain-derived exosomes in Alzheimer’s Disease. NEURO-NET captures exosomes secreted from various brain cells. Exosomes provide a “fingerprint” of the…
Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging
Posted: 27 June 2024 Telix today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET1 agent, TLX250-CDx (Zircaix®2, 89Zr-DFO-girentuximab), for the…
MCRI and Incepta Pharmaceuticals partner to protect children from rotavirus
Posted: 27 June 2024 Murdoch Children’s Research Institute (MCRI) and Incepta Pharmaceuticals, based in Bangladesh, have embarked on a collaboration aimed at bringing life-saving innovation to the global healthcare landscape. MCRI has announced the signing of a non-exclusive licensing…
